Zymogenetics, Inc.

Other

Whitehead Institute for Biomedical Research

The Government of the United States of America

Bristol-myers Squibb Compnay

University of Washington

Health Research Inc., Roswell Park Division

Health Research Inc. Rosewell Park Division

Steven D Levin

Scott R Presnell

Katherine E Lewis

Stephen R Jaspers

Zeren Gao

Monica J Huber

Robert Mabry

Mark W Rixon

James William West

Janine M Bilsborough

Rolf E Kuestner

Harvey F Lodish

Warren Jaye Leonard

Cameron Brandt

Eric Chadwick

Heinz Baumann

Andrew G Farr

George Robert Mabry, Iii

Akhilesh Pandey

Katsutoshi Ozaki

Gao Zeren

Margaret Dow Moore

David W Taft

Steven K Burkhead

Frederick J Ramsdell

Craig Ostrander

Megan M Lantry

Brent Meengs

Robert J Rosler

William A Swenson

Anitra Wolf

Eric M Chadwick

Monica Huber

Edward D Howard

The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.

Treating inflammation with IL-17/IL-23 bispecific antibodies

The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is expressed on T cells. The present invention also provides the discovery of zB7R1's ability to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided.

Method of treating CD155 expressing cancers

The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and IL-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.

Use of an IL-17/IL-23 bispecific antibody for treating inflammation

Screening method for inhibitors of binding of zBR7R1 to CD155

Polynucleotides encoding antagonists of IL-17A, IL-17F, and IL-23p19

Antagonists of IL-17A, IL-17F, and IL-23P19

Compositions and methods relating to soluble dimeric proteins are disclosed. The dimeric proteins comprise first and second polypeptide fusions linked via a dimerizing domain, each polypeptide fusion comprising first and second monomer domains corresponding to a cytokine or an extracellular domain of a cell-surface receptor. The monomer domains may be positioned amino terminal and carboxyl terminal to the dimerizing domain. Alternatively, the monomer domains may be positioned in tandem, either carboxyl terminal or amino terminal to the dimerizing domain. The dimeric proteins are useful in methods for therapy, diagnosis, and research.

Dimeric fusion proteins and related compositions and methods

Methods of inhibiting inflammation with antagonists to IL-17A, IL-17F, and IL-23P19

The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. ZcytoR14 is a common receptor for IL-17A and IL-17F. The present invention includes soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners, as well as methods for antagonizing IL-17F, IL-17A or both IL-17A and IL-17F using such soluble receptors, antibodies and binding partners.

Methods of treating multiple sclerosis (MS) using an IL-17A and IL-17F antagonist

Disclosed are antagonists of IL-17A and IL-17F. The antagonists are based on soluble IL-17RA and IL-17RC fusion proteins, including hybrid soluble receptors comprising portions of both IL-17RC and IL-17RA ('IL-17RC/IL-17RA'). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. Also disclosed are methods of using such antagonists for treating disease, particularly inflammatory diseases mediated at least in part by IL-17A and/or IL-17F.

Methods of treating inflammation using soluble IL-17RA/RC fusion proteins

The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17, IL-23 via it's p19 subunit or both IL-17 and IL-23 (via p19). IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.

IL-23 antagonists

The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. IL-17RC is a common receptor for IL-17A and IL-17F. The present invention includes methods of using a soluble IL-17RC receptor, IL-17RCx4 for treating inflammation.

Soluble IL-17RCx4 and fusion proteins thereof

Soluble IL-17RA/RC fusion proteins and related methods

Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use

Growing community of inventors

Seattle, WA, United States of America

Steven D Levin